Vertex Acquires An Undisclosed Discovery-Stage GPCR Program From Septerna; Septerna To Receive $47.5M Upfront And Additional Potential Future Payments
Portfolio Pulse from Benzinga Newsdesk
Vertex Pharmaceuticals has acquired an undisclosed discovery-stage GPCR program from Septerna. The deal includes a $47.5 million upfront payment and additional potential future payments upon achieving a preclinical milestone and for use of Septerna's GPCR Native Complex™ Platform.
September 12, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex's acquisition of a GPCR program from Septerna could potentially enhance its drug discovery pipeline, depending on the success of the program. The $47.5M upfront payment is a significant investment.
The acquisition could potentially enhance Vertex's drug discovery pipeline, which would be positive for the company. However, the success of the program and the return on the upfront investment are uncertain at this stage.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100